SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy shares are experiencing significant volatility as investors weigh the company's long-term potential in powering data centers against broader concerns over data center project moratoriums and energy demands. The community remains divided, with some traders viewing the recent price dips as buying opportunities based on upcoming earnings and potential contract developments, while others warn of ongoing manipulation and negative sector sentiment.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies shares are trending following a "blowout" second-quarter report that featured record revenue and earnings that significantly exceeded Wall Street expectations. The company also sharply raised its full-year outlook, fueling optimism regarding the durability of AI server demand and the company's position within the infrastructure buildout.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending as traders debate the stock's persistent price decline and lack of momentum, with many users expressing frustration over the company's inability to break resistance levels or secure S&P 500 inclusion. While some investors view the current price as an undervalued long-term buying opportunity, others are pivoting to fintech competitors like Robinhood, citing superior platform innovation and performance.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as traders react to rising Treasury yields, higher oil prices driven by escalating Middle East tensions, and ongoing labor market uncertainty. While some investors fear a potential market downturn due to these macro headwinds, others are focused on 'buy the dip' opportunities and optimism surrounding AI-related earnings strength.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The community discussion is fragmented, with significant debate centered on the impact of rising oil prices and U.S. Treasury yields amid escalating geopolitical tensions. Traders are also actively analyzing the potential for Federal Reserve interest rate hikes and reacting to the mixed implications of recent economic data releases.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology shares are experiencing significant volatility following a fiscal first-quarter earnings report that featured a revenue beat but sparked investor concerns over margin compression, rising operating expenses, and a cooling pace of growth. While some traders view the resulting sell-off as an attractive buying opportunity based on the company's long-term AI connectivity outlook, others are cautious due to skinnier-than-expected guidance and broader macroeconomic headwinds.

GitLab, Inc. engages in the intelligent development, security, and operations (DevSecOps) platform for software innovation. It enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab shares experienced a strong rally following an earnings report that exceeded revenue and profit expectations, alongside a raised full-year outlook. The community remains divided between those viewing the beat as a bullish indicator of durable AI-driven growth and skeptics who highlight persistent operating losses and concerns about the sustainability of the company's growth trajectory.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB shares experienced high volatility following a fiscal Q2 earnings report that featured revenue and earnings beats alongside an updated full-year forecast. While some traders were encouraged by the growth, the shares faced pressure as investors focused on Atlas revenue growth missing higher-end expectations and a sequential moderation in forward guidance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid rising oil prices driven by escalating geopolitical tensions in the Middle East following fresh U.S. military strikes on Iranian targets. Traders remain divided on the outlook for the energy sector, with some highlighting supply constraints and inflation concerns while others speculate that recent supply agreements may eventually pressure prices downward.

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Alumis Inc.

Alumis is trending following a massive share price decline after the company reported that its Phase 2b LUMUS trial for a lupus treatment failed to meet its primary and secondary endpoints. While investors are debating the severity of the setback and potential dilution risks, many in the community emphasize that the psoriasis program remains on track for a near-term NDA filing and believe the market may have overreacted to the lupus trial results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026...

AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year

Agios tops Q2 revenue and earnings estimates as Aqvesme's launch and Pyrukynd sales fuel growth, while advancing its hematology pipeline.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026...

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +9.14% and +97.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals

HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss? 

Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.

Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?

NBIX heads into Q2 results with a focus on Ingrezza sales, Crenessity growth and pipeline updates as investors watch key commercial and clinical progress.

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program

Agios drops after ending tebapivat development for SCD as phase II data confirmed PK activation but failed to show sufficient clinical differentiation.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Why Is AGIO Stock Falling Today? 

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.21	--	--	N/A
Q2 '26	-$1.65	-$1.69	-2.13%	MISSED
Q1 '26	-$1.80	-$1.69	6.29%	BEAT
Q4 '25	-$1.95	-$1.86	4.80%	BEAT
Q3 '25	-$1.90	-$1.78	6.14%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '26

Historical Earnings